NASDAQ · ECOR

electroCore, Inc.

$6.05 -$0.14 (-2.26%) 1D Market open

Key Metrics

$51.35M
Market cap
P/E · TTM
$34.90M
Revenue · TTM
−$15.38M
Net income
EPS · TTM $-1,855.71
Dividend yield
Free cash flow −$6.87M
Beta · 1Y 1.98
EBITDA · TTM
Gross margin 87.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    From its Jun 1 high, the share price fell 44%.

    Peak close $10.35 on Jun 1; trough close $5.78 on Jul 16. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -44%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 8
    The stock moved -17.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 8
  • May 26
    The stock moved +33.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$51.35M
Enterprise value$48.96M
Shares outstanding8.3M
52-wk range$4.16 – $10.50
Avg volume · 20D73.4K
Net cash $2.39M
Book value / share$-686.21
IndustryElectromedical & Electrotherapeutic Apparatus
ExchangeNASDAQ
About electroCore, Inc.
IPO dateJun 22, 2018
Employees83

electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.47
P/FCF
EV/EBITDA
EV/Sales1.40
Graham №

Profitability

Gross 87.2%
Operating -44.9%
Net -44.1%
FCF -19.7%
ROE / ROIC -1,657.5% · 190.3%

Financial Health

Current ratio1.02
Quick ratio0.86
Debt / equity-1.13
Debt / EBITDA
Net cash $2.39M
Working capital$213.00K

Cash Flow · TTM

Operating CF −$6.84M
Capex −$31.00K
Free cash flow −$6.87M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-17.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings